Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Strong participation of Gustave Roussy at the ESMO 2022 congress
The annual congress of the European Society of Medical Oncology (ESMO) will be held in Paris from September 9 to 13, 2022. This major cancer research event will present the main advances in clinical research. Gustave Roussy is one of the major players in this event and will, at this occasion, announce the launch of its Alumni network.
Published on
Changed on
The annual congress of the European Society of Medical Oncology (ESMO) will be held in Paris from September 9 to 13, 2022. This major cancer research event will present the main advances in clinical research. Gustave Roussy is one of the major players in this event and will, at this occasion, announce the launch of its Alumni network.
After two virtual editions, the ESMO congress is back as a physical event. Each year, it brings together more than 20,000 international cancer specialists: doctors, researchers, industrialists, and patient representatives.
Gustave Roussy experts at the meeting
Gustave Roussy's physician-researchers will participate in, lead or moderate several major sessions and highlights of the congress. Prof. Fabrice André, co-chairman of the scientific committee of the congress, will participate in the opening session, co-chair the presidential session on Saturday, September 10 and introduce one of the three keynote lectures. Dr. Suzette Delaloge, medical oncologist and Director of the Interception Program, will comment on a major study by Dr. Charles Swanton on the role of pollution on lung cancer. Two physicians from the Institute, Prof. Laurence Albiges and Dr. Bernard Escudier, are also co-authors of two studies presented in the presidential session.
Two award-winning physician-researchers
Among the 4 prestigious awards given by ESMO, 2 are awarded this year to Gustave Roussy physicians-researchers.
Prof. Karim Fizazi, medical oncologist, receives the ESMO Award 2022 for his exceptional contribution to advances in prostate cancer and testicular cancer.
Dr. Bernard Escudier, medical oncologist and specialist in the management of kidney cancer, receives the ESMO Lifetime Achievement Award for his lifetime achievement.
Gustave Roussy's main presentations
This year, the Institute's physician-researchers will present 4 studies in proffered papers (oral sessions), 17 mini-orals and 37 posters. The 4 oral sessions will be held by :
- Dr. Rayan Kabirian, who analyzed the impact of localized breast cancer treatments on induced amenorrhea and quality of life in non-menopausal women.
► Read the press release - Prof. Laurence Albiges will present the results of the phase II KEYNOTE-B61 study on the combination of immunotherapy and targeted therapy (anti-angiogenic) in the first-line treatment of non-clarified kidney cancer.
- Dr. Antoine Hollebecque will present the first results in humans of an ultra-targeted therapy (FGFR2 gene) in patients with biliary tract cancer (ReFocus trial).
► Read the press release - Dr. Eric Baudin evaluated the efficacy of an innovative treatment: internal vectorized radiotherapy in pancreatic neuroendocrine tumors (OCLURANDUM trial).
► Read the press release
Gustave Roussy creates its Alumni network
On the occasion of this congress bringing together cancer professionals from all over the world, some of whom were trained at Gustave Roussy, the Institute launches the Gustave Roussy Alumni. The aim is to build a collaborative and participative network that will be a catalyst for future projects.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
